Abstract
Introduction: There is increasing need for more testing in non-small cell lung cancer given the introduction of newer targeted therapies. Cytological specimens including conventional smears (CS), cell blocks (CB), and liquid-based cytology (LBC) are an alternative to histologic tissue (HT) specimens in detecting EGFR mutations, but the concordance of these 2 specimens is yet to be determined. The aim of the present systematic review is to determine the concordance rates between different cytologic specimens with HT in detecting EGFR mutations. Methods: PubMed, Cochrane Library, and Google Scholar were utilized in the primary search, along with reference lists of electronically retrieved full-text articles. Concordance rates were pooled together if 2 or more studies reporting the same type of cytologic specimen were available. Results: Overall, 15 studies were included in this review, with 13 studies included in the pooled analysis. There was an overall concordance rate of 92.8% in 593 paired cytologic and HT specimens, with LBC having the highest concordance rate of 96.0%, followed by CS and CB, each with a concordance rate of 95.8%, although the concordance rate of CS and/or CB was lower at 90.6% with a larger pool of studies. LBC was found to have a significantly higher concordance rate than CS and/or CB. Conclusion: Cytological specimens have a high concordance rate in detecting EGFR mutations, when compared to HT. LBC has shown superior concordance rates compared to CS and CB. Cytological specimens should be considered as an additional and alternative source of diagnostic material for EGFR testing.
References
1.
Bray
F
, Ren
JS
, Masuyer
E
, Ferlay
J
. Global estimates of cancer prevalence for 27 sites in the adult population in 2008
. Int J Cancer
. 2013 Mar 1
;132
(5
):1133
–45
. .2.
Didkowska
J
, Wojciechowska
U
, Mańczuk
M
, Łobaszewski
J
. Lung cancer epidemiology: contemporary and future challenges worldwide
. Ann Transl Med
. 2016 Apr
;4
(8
):150
. .3.
Hanly
PA
, Sharp
L
. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden
. BMC Cancer
. 2014 Mar 26
;14
:224
. .4.
Duma
N
, Santana-Davila
R
, Molina
JR
. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment
. Mayo Clin Proc
. 2019 Aug
;94
(8
):1623
–40
. .5.
Rusch
V
, Baselga
J
, Cordon-Cardo
C
, Orazem
J
, Zaman
M
, Hoda
S
, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
. Cancer Res
. 1993 May 15
;53
(10 Suppl
):2379
–85
.6.
Lynch
TJ
, Bell
DW
, Sordella
R
, Gurubhagavatula
S
, Okimoto
RA
, Brannigan
BW
, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
. N Engl J Med
. 2004 May 20
;350
(21
):2129
–39
. .7.
Soria
JC
, Ohe
Y
, Vansteenkiste
J
, Reungwetwattana
T
, Chewaskulyong
B
, Lee
KH
, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
. N Engl J Med
. 2018 Jan 11
;378
(2
):113
–25
. .8.
Bubendorf
L
, Lantuejoul
S
, de Langen
AJ
, Thunnissen
E
. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: number 2 in the series “pathology for the clinician” edited by Peter Dorfmuller and Alberto Cavazza
. Eur Respir Rev
. 2017 Jun 30
;26
(144
):170007
.9.
Wong
SQ
, Li
J
, Tan
AY
, Vedururu
R
, Pang
JM
, Do
H
, Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing
. BMC Med Genomics
. 2014 May 13
;7
:23
. .10.
Boldrini
L
, Gisfredi
S
, Ursino
S
, Camacci
T
, Baldini
E
, Melfi
F
, Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis
. J Thorac Oncol
. 2007 Dec
;2
(12
):1086
–90
. .11.
Malapelle
U
, de Rosa
N
, Rocco
D
, Bellevicine
C
, Crispino
C
, Illiano
A
, EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study
. J Clin Pathol
. 2012 Jan
;65
(1
):87
–91
. .12.
Dong
Z
, Cao
Z
, Wu
W
, Zhang
L
, Hou
L
, Zhang
W
, Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples
. J Thorac Dis
. 2020 Sep
;12
(9
):4941
–9
. .13.
Wu
W
, Cao
Z
, Zhang
W
, Zhang
L
, Hou
L
, Wu
C
. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
. Diagn Pathol
. 2020 Jan 31
;15
(1
):9
. .14.
Reynolds
JP
, Zhou
Y
, Jakubowski
MA
, Wang
Z
, Brainard
JA
, Klein
RD
, Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples
. Cancer Cytopathol
. 2017 Mar
;125
(3
):178
–87
. .15.
Page
MJ
, McKenzie
JE
, Bossuyt
PM
, Boutron
I
, Hoffmann
TC
, Mulrow
CD
, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
. BMJ
. 2021 Mar 29
;372
:n71
. .16.
Whiting
PF
, Rutjes
AW
, Westwood
ME
, Mallett
S
, Deeks
JJ
, Reitsma
JB
, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
. Ann Intern Med
. 2011 Oct 18
;155
(8
):529
–36
. .17.
Aisner
DL
, Deshpande
C
, Baloch
Z
, Watt
CD
, Litzky
LA
, Malhotra
B
, Evaluation of EGFR mutation status in cytology specimens: an institutional experience
. Diagn Cytopathol
. 2013 Apr
;41
(4
):316
–23
. .18.
Khode
R
, Larsen
DA
, Culbreath
BC
, Parrish
S
, Walker
KL
, Sayage-Rabie
L
, Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas
. Cancer Cytopathol
. 2013 Jul
;121
(7
):361
–9
. .19.
Liu
X
, Lu
Y
, Zhu
G
, Lei
Y
, Zheng
L
, Qin
H
, The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
. J Clin Pathol
. 2013 Dec
;66
(12
):1065
–9
. .20.
Sun
PL
, Jin
Y
, Kim
H
, Lee
CT
, Jheon
S
, Chung
JH
. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas
. Cancer Cytopathol
. 2013 Jun
;121
(6
):311
–9
. .21.
Heymann
JJ
, Bulman
WA
, Maxfield
RA
, Powell
CA
, Halmos
B
, Sonett
J
, Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples
. Cytojournal
. 2014
;11
:12
. .22.
Wu
CY
, Hou
LK
, Ren
SX
, Su
B
, Chen
G
. High feasibility of liquid-based cytological samples for detection of EGFR mutations in Chinese patients with NSCLC
. Asian Pac J Cancer Prev
. 2014
;15
(18
):7885
–9
. .23.
Liu
J
, Zhao
R
, Zhang
J
, Zhang
J
. ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
. J Cancer Res Clin Oncol
. 2015 Feb
;141
(2
):221
–7
. .24.
Min
KW
, Kim
WS
, Jang
SJ
, Choi
YD
, Chang
S
, Jung
SH
, MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study
. J Cancer Res Clin Oncol
. 2016 Oct
;142
(10
):2209
–16
. .25.
Satouchi
M
, Tanaka
H
, Yoshioka
H
, Shimokawaji
T
, Mizuno
K
, Takeda
K
, Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas((R)) EGFR mutation test
. Lung Cancer
. 2017 Sep
;111
:190
–4
.26.
Zhao
H
, Qiu
T
, Guo
H
, Ying
J
, Li
J
, Zhang
Z
. Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma
. Oncotarget
. 2017 Dec 5
;8
(63
):106685
–92
. .27.
Asaka
S
, Yoshizawa
A
, Nakata
R
, Negishi
T
, Yamamoto
H
, Shiina
T
, Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: comparison between cell pellets, cell blocks and matching tissue specimens
. Oncol Lett
. 2018 Feb
;15
(2
):1469
–74
. .28.
Su
F
, Fu
Y
, Wu
Q
, Zheng
K
, Tang
Y
, Su
X
, High concordance of EGFR mutation status between sputum and corresponding tissue specimens of late-stage lung cancers using amplification refractory mutation system-PCR
. Int J Clin Exp Pathol
. 2018
;11
(5
):2683
–90
.29.
Zhang
Y
, Li
J
, Hua
P
, Liu
N
, Li
Q
, Zhu
X
, Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma
. Int J Clin Exp Pathol
. 2018
;11
(7
):3647
–55
.30.
Satoh
Y
, Matsuo
Y
, Kuba
T
, Yamashita
K
, Sawano
M
, Tozaka
S
, EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer
. Virchows Archiv
. 2019
:1
–10
.31.
Tanaka
R
, Ohtsuka
K
, Ogura
W
, Arai
N
, Yoshida
T
, Nakazato
Y
, Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations
. Diagn Cytopathol
. 2020
;48
(6
):516
–23
. .32.
da Cunha Santos
G
, Saieg
MA
, Geddie
W
, Leighl
N
. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities
. Cancer Cytopathol
. 2011
;119
(2
):80
–91
. .33.
Kawaraya
M
, Gemba
K
, Ueoka
H
, Nishii
K
, Kiura
K
, Kodani
T
, Evaluation of various cytological examinations by bronchoscopy in the diagnosis of peripheral lung cancer
. Br J Cancer
. 2003 Nov 17
;89
(10
):1885
–8
. .34.
Govert
JA
, Kopita
JM
, Matchar
D
, Kussin
PS
, Samuelson
WM
. Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor
. Chest
. 1996 Feb
;109
(2
):451
–6
. .35.
Vivero
M
, Wang
CI
, Jo
VY
, Hollowell
M
, Cibas
ES
, Lindeman
NI
, Molecular testing of different cytologic preparations in patients with advanced lung adenocarcinoma: which yields the best results?
J Am Soc Cytopathol
. 2017 Jan–Feb
;6
(1
):16
–23
. .36.
Bedard
PL
, Hansen
AR
, Ratain
MJ
, Siu
LL
. Tumour heterogeneity in the clinic
. Nature
. 2013 Sep 19
;501
(7467
):355
–64
. .37.
Jamal-Hanjani
M
, Wilson
GA
, McGranahan
N
, Birkbak
NJ
, Watkins
TBK
, Veeriah
S
, Tracking the evolution of non-small-cell lung cancer
. N Engl J Med
. 2017 Jun 1
;376
(22
):2109
–21
. .38.
Gerlinger
M
, Rowan
AJ
, Horswell
S
, Math
M
, Larkin
J
, Endesfelder
D
, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
. N Engl J Med
. 2012 Mar 8
;366
(10
):883
–92
. .39.
Gow
CH
, Chang
YL
, Hsu
YC
, Tsai
MF
, Wu
CT
, Yu
CJ
, Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
. Ann Oncol
. 2009 Apr
;20
(4
):696
–702
. .40.
Piotrowska
Z
, Niederst
MJ
, Karlovich
CA
, Wakelee
HA
, Neal
JW
, Mino-Kenudson
M
, Heterogeneity underlies the emergence of EGFRT790 Wild-Type Clones Following treatment of T790M-positive cancers with a third-generation EGFR inhibitor
. Cancer Discov
. 2015 Jul
;5
(7
):713
–22
. .41.
Majem
M
, Remon
J
. Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients
. Transl Lung Cancer Res
. 2013 Jun
;2
(3
):226
–37
. .42.
Tian
P
, Wang
Y
, Li
L
, Zhou
Y
, Luo
W
, Li
W
. CT-guided transthoracic core needle biopsy for small pulmonary lesions: diagnostic performance and adequacy for molecular testing
. J Thorac Dis
. 2017 Feb
;9
(2
):333
–43
. .43.
Chouaid
C
, Dujon
C
, Do
P
, Monnet
I
, Madroszyk
A
, Le Caer
H
, Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)
. Lung Cancer
. 2014 Nov
;86
(2
):170
–3
. .44.
Nosaki
K
, Satouchi
M
, Kurata
T
, Yoshida
T
, Okamoto
I
, Katakami
N
, Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study
. Lung Cancer
. 2016 Nov
;101
:1
–8
. .45.
Heerink
WJ
, de Bock
GH
, de Jonge
GJ
, Groen
HJ
, Vliegenthart
R
, Oudkerk
M
. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis
. Eur Radiol
. 2017 Jan
;27
(1
):138
–48
. .46.
Crowley
E
, Di Nicolantonio
F
, Loupakis
F
, Bardelli
A
. Liquid biopsy: monitoring cancer-genetics in the blood
. Nat Rev Clin Oncol
. 2013 Aug
;10
(8
):472
–84
. .47.
Park
S
, Hur
JY
, Lee
KY
, Lee
JC
, Rho
JK
, Shin
SH
, Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid
. Clin Chem Lab Med
. 2017 Aug 28
;55
(10
):1489
–95
. .48.
Lee
JS
, Hur
JY
, Kim
IA
, Kim
HJ
, Choi
CM
, Lee
JC
, Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA
. BMC Cancer
. 2018 Dec 10
;18
(1
):1236
. .49.
Park
J
, Lee
C
, Eom
JS
, Kim
MH
, Cho
YK
. Detection of EGFR mutations using bronchial washing-derived extracellular vesicles in patients with non-small-cell lung carcinoma
. Cancers
. 2020 Sep 30
;12
(10
). .50.
Dejmek
A
, Zendehrokh
N
, Tomaszewska
M
, Edsjö
A
. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality
. Cancer Cytopathol
. 2013 Jul
;121
(7
):344
–53
. .51.
Arbyn
M
, Andersson
K
, Bergeron
C
, Bogers
JP
, von Knebel-Doebertitz
M
, Dillner
J
. Cervical cytology biobanks as a resource for molecular epidemiology
. Methods Mol Biol
. 2011
;675
:279
–98
. .52.
Rait
VK
, Zhang
Q
, Fabris
D
, Mason
JT
, O’Leary
TJ
. Conversions of formaldehyde-modified 2′-deoxyadenosine 5′-monophosphate in conditions modeling formalin-fixed tissue dehydration
. J Histochem Cytochem
. 2006 Mar
;54
(3
):301
–10
. .53.
Ellison
G
, Zhu
G
, Moulis
A
, Dearden
S
, Speake
G
, McCormack
R
. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
. J Clin Pathol
. 2013
;66
(2
):79
–89
. .54.
Yatabe
Y
, Kerr
KM
, Utomo
A
, Rajadurai
P
, Tran
VK
, Du
X
, EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey
. J Thorac Oncol
. 2015 Mar
;10
(3
):438
–45
. .55.
Angulo
B
, Conde
E
, Suárez-Gauthier
A
, Plaza
C
, Martínez
R
, Redondo
P
, A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry
. PLoS One
. 2012
;7
(8
):e43842
. .56.
Surrey
LF
, Oakley
FD
, Merker
JD
, Long
TA
, Vasalos
P
, Moncur
JT
, Next-generation sequencing (NGS) methods show superior or equivalent performance to non-NGS methods on BRAF, EGFR, and KRAS proficiency testing samples
. Arch Pathol Lab Med
. 2019 Aug
;143
(8
):980
–4
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
